Literature DB >> 6807795

Comparison of different methods expressing results of the aminopyrine breath test.

D A Schoeller, A L Baker, P S Monroe, P S Krager, J F Schneider.   

Abstract

Different methods of expressing the results of the aminopyrine CO2 breath test (ABT) were compared to determine the method that would be most sensitive for evaluating liver function. The patient population included health controls (n = 22); patients with mild (4), moderate (9), and severe (7) alcoholic liver disease; and patients with chronic persistent hepatitis (7), chronic active hepatitis (18), chronic active hepatitis with bridging (18), and chronic active hepatitis with cirrhosis (17). The ABT was performed with 2 micro Ci [14C]aminopyrine or 2 mg per kg [13C]aminopyrine, and the results were expressed as the instantaneous labeled CO2 excretion rates at 30, 60, 90, and 120 min after the dose, the maximum excretion rate, and the 120-min cumulative excretion. The 30-min parameter had the highest sensitivity toward moderate alcoholic hepatitis, severe alcoholic hepatitis, chronic active hepatitis with bridging, and chronic active hepatitis with cirrhosis (96%); however, when the ABT was repeated in six normal controls with 225 ml of orange juice, the 30-min rate was significantly reduced (7.8 +/- 1.3 vs. 5.6 +/- 1.2% dose per hr), and the rate of false-positive test results was increased (0 of 6 vs. 2 of 6) indicating that gastric delay influenced the 30-min parameter. The 60-min excretion rate, maximum rate, and 120-min cumulative excretion were the next most sensitive expressions of the ABT, and were not altered by the small gastric load. Of these three expressions, the 60-min parameter was the most convenient because it required fewer samples and a shorter test period.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6807795     DOI: 10.1002/hep.1840020411

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  13C breath test for measurement of liver function.

Authors:  M Becker
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

2.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

3.  Aminopyrine breath test.

Authors:  F Perri; M Pastore; A Andriulli
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

4.  [13C]methacetin breath test for evaluation of liver damage.

Authors:  K Matsumoto; M Suehiro; M Iio; T Kawabe; Y Shiratori; K Okano; T Sugimoto
Journal:  Dig Dis Sci       Date:  1987-04       Impact factor: 3.199

5.  Effect of liver disease on the kinetics of lactate removal after heavy exercise.

Authors:  R Casaburi; S Oi
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1989

6.  Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; H Seyfert; M Weber; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

7.  Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.

Authors:  Gadi Lalazar; Tomer Adar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

8.  A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT.

Authors:  G Lalazar; O Pappo; T Hershcovici; T Hadjaj; M Shubi; H Ohana; N Hemed; Y Ilan
Journal:  J Viral Hepat       Date:  2008-07-11       Impact factor: 3.728

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.